News Feed

MPN News

MPN rss feedThe MPN News feed provides frequent updates on the latest happenings in the MPN World. Fresh content, with brief summary is automatically updated frequently from reliable sources.  Just click on the red hyperlink to pull up the complete news item.

Make PV Reporter your “starting point” for all MPN related news.

As the myeloproliferative neoplasm (MPN) associated with the most complications and the shortest life expectancy, myelofibrosis (MF) has been the focus of the majority of research and advances in the field. Although ruxolitinib (Jakafi) still remains the only FDA-approved agent for treatment of this disease, there are several drugs in development. [...]
Wed, Jan 23, 2019, Continue reading at the source
SEATTLE, Dec. 28, 2018 /PRNewswire/ — CTI BioPharma Corp. (NASDAQ: CTIC) announced today the completion of full enrollment of 150 patients in the PAC203 Phase 2 study of pacritinib. The Company expects to report the determination of the optimal dose of pacritinib in mid-2019 following a meeting with the U.S. [...]
Wed, Jan 09, 2019, Continue reading at the source
The University of Texas MD Anderson Cancer Center and Ascentage Pharma Group, Inc. today announced a five-year strategic collaboration agreement to advance the development of five potential new cancer therapies. The alliance is aimed at developing novel cancer therapeutics based upon Ascentage's proprietary Protein-Protein Interaction drug discovery technology platform. MD Anderson's [...]
Wed, Jan 09, 2019, Continue reading at the source
In memory of Jordan In 2014, our daughter Jordan, age 14, complained of headaches and neck pain. Ultimately the doctors diagnosed her with mastoiditis, with a rare complication of cerebral venous sinus thrombosis (a 5% chance of that complication). The doctors then fixated on a diagnosis of migraines before, during and [...]
Wed, Jan 09, 2019, Continue reading at the source
CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) — Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today provided an update on progress in the MANIFEST Phase 2 clinical trial of CPI-0610 in myelofibrosis (MF). The Company also reviewed [...]
Mon, Jan 07, 2019, Continue reading at the source
The applications for the second found of MF Challenge funding will be reviewed on Friday, May 31st in Chicago. In addition to members of the Foundation's Scientific Advisory Board, thought leaders from fibrosis will be joining the review panel as the proposals are judged. In addition to scientific merit, the [...]
Sun, May 26, 2013, Continue reading at the source


error: Content is protected !
Malcare WordPress Security